Leveraging stewardship to promote ceftriaxone use in severe infections with low- and no-risk AmpC Enterobacterales

Article Infectious Diseases

Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study

Alexis Maillard et al.

Summary: The optimal treatment regimen for infections caused by wild-type AmpC beta-lactamase-producing Enterobacterales remains controversial. This study compared the outcomes of bloodstream infections (BSI) and pneumonia according to different types of definitive antibiotic therapy, and found that treatment with 3GC or piperacillin +/- tazobactam was not associated with higher mortality but had an increased risk of treatment failure.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)

添加到收藏夹

Article Immunology

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections

Pranita D. Tamma et al.

Summary: The Infectious Diseases Society of America (IDSA) has provided updated guidance on the treatment of antimicrobial-resistant infections, focusing on treating AmpC-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. The guidance is based on clinical experience, expert opinion, and a review of available literature, as published data on optimal treatment options are limited. This document emphasizes treatment approaches for infections in the United States, considering differences in resistance epidemiology and the availability of specific anti-infectives internationally.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Review Infectious Diseases